1
|
Torequl Islam M, Shimul Bhuia M, Paulo Martins de Lima J, Paulo Araujo Maia F, Beatriz Herminia Ducati A, Douglas Melo Coutinho H. Phytanic acid, an inconclusive phytol metabolite: A review. Curr Res Toxicol 2023; 5:100120. [PMID: 37744206 PMCID: PMC10515296 DOI: 10.1016/j.crtox.2023.100120] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2023] [Revised: 07/28/2023] [Accepted: 08/30/2023] [Indexed: 09/26/2023] Open
Abstract
Phytanic acid (PA: 3,7,11,15-tetramethylhexadecanoic acid) is an important biometabolite of the chlorophyll-derived diterpenoid phytol. Its biological sources (occurrence) and ADME (absorption, distribution, metabolism, and elimination) profile are well-discussed in the literature. Cumulative literature suggests that PA has beneficial as well as harmful biological roles in humans and other animals. This study aimed to sketch a brief summary of PA's beneficial and harmful pharmacological effects in test systems on the basis of existing literature reports. Literature findings propose that PA has anti-inflammatory and immunomodulatory, antidiabetic, anti-obesity, anticancer, and oocyte maturation effects. Although a high plasma PA-level mediated SLS remains controversial, it is evident to link it with Refsum's disease and other peroxisomal enzyme deficiency diseases in humans, including RCDP and LD; ZHDA and Alzheimer's disease; progressive ataxia and dysarthria; and an increased risk of some lymphomas such as LBL, FL, and NHL. PA exerts toxic effects on different kinds of cells, including neuronal, cardiac, and renal cells, through diverse pathways such as oxidative stress, mitochondrial disturbance, apoptosis, disruption of Na+/K+-ATPase activity, Ca2+ homeostasis, alteration of AChE and MAO activities, etc. PA is considered a cardiac biomarker in humans. In conclusion, PA may be one of the most important biometabolites in humans.
Collapse
Affiliation(s)
- Muhammad Torequl Islam
- Department of Pharmacy, Bangabandhu Sheikh Mujibur Rahman Science and Technology University, Gopalganj 8100, Bangladesh
| | - Md. Shimul Bhuia
- Department of Pharmacy, Bangabandhu Sheikh Mujibur Rahman Science and Technology University, Gopalganj 8100, Bangladesh
| | | | | | | | | |
Collapse
|
2
|
Kocherlakota S, Swinkels D, Van Veldhoven PP, Baes M. Mouse Models to Study Peroxisomal Functions and Disorders: Overview, Caveats, and Recommendations. Methods Mol Biol 2023; 2643:469-500. [PMID: 36952207 DOI: 10.1007/978-1-0716-3048-8_34] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/27/2023]
Abstract
During the last three decades many mouse lines were created or identified that are deficient in one or more peroxisomal functions. Different methodologies were applied to obtain global, hypomorph, cell type selective, inducible, and knockin mice. Whereas some models closely mimic pathologies in patients, others strongly deviate or no human counterpart has been reported. Often, mice, apparently endowed with a stronger transcriptional adaptation, have to be challenged with dietary additions or restrictions in order to trigger phenotypic changes. Depending on the inactivated peroxisomal protein, several approaches can be taken to validate the loss-of-function. Here, an overview is given of the available mouse models and their most important characteristics.
Collapse
Affiliation(s)
- Sai Kocherlakota
- Laboratory of Cell Metabolism, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium
| | - Daniëlle Swinkels
- Laboratory of Cell Metabolism, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium
| | - Paul P Van Veldhoven
- Laboratory of Peroxisome Biology and Intracellular Communication, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium
| | - Myriam Baes
- Laboratory of Cell Metabolism, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
| |
Collapse
|
3
|
Mice with a deficiency in Peroxisomal Membrane Protein 4 (PXMP4) display mild changes in hepatic lipid metabolism. Sci Rep 2022; 12:2512. [PMID: 35169201 PMCID: PMC8847483 DOI: 10.1038/s41598-022-06479-y] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2020] [Accepted: 01/31/2022] [Indexed: 11/08/2022] Open
Abstract
Peroxisomes play an important role in the metabolism of a variety of biomolecules, including lipids and bile acids. Peroxisomal Membrane Protein 4 (PXMP4) is a ubiquitously expressed peroxisomal membrane protein that is transcriptionally regulated by peroxisome proliferator-activated receptor α (PPARα), but its function is still unknown. To investigate the physiological function of PXMP4, we generated a Pxmp4 knockout (Pxmp4-/-) mouse model using CRISPR/Cas9-mediated gene editing. Peroxisome function was studied under standard chow-fed conditions and after stimulation of peroxisomal activity using the PPARα ligand fenofibrate or by using phytol, a metabolite of chlorophyll that undergoes peroxisomal oxidation. Pxmp4-/- mice were viable, fertile, and displayed no changes in peroxisome numbers or morphology under standard conditions. Also, no differences were observed in the plasma levels of products from major peroxisomal pathways, including very long-chain fatty acids (VLCFAs), bile acids (BAs), and BA intermediates di- and trihydroxycholestanoic acid. Although elevated levels of the phytol metabolites phytanic and pristanic acid in Pxmp4-/- mice pointed towards an impairment in peroxisomal α-oxidation capacity, treatment of Pxmp4-/- mice with a phytol-enriched diet did not further increase phytanic/pristanic acid levels. Finally, lipidomic analysis revealed that loss of Pxmp4 decreased hepatic levels of the alkyldiacylglycerol class of neutral ether lipids, particularly those containing polyunsaturated fatty acids. Together, our data show that while PXMP4 is not critical for overall peroxisome function under the conditions tested, it may have a role in the metabolism of (ether)lipids.
Collapse
|
4
|
Khalil Y, Carrino S, Lin F, Ferlin A, Lad HV, Mazzacuva F, Falcone S, Rivers N, Banks G, Concas D, Aguilar C, Haynes AR, Blease A, Nicol T, Al-Shawi R, Heywood W, Potter P, Mills K, Gale DP, Clayton PT. Tissue Proteome of 2-Hydroxyacyl-CoA Lyase Deficient Mice Reveals Peroxisome Proliferation and Activation of ω-Oxidation. Int J Mol Sci 2022; 23:ijms23020987. [PMID: 35055171 PMCID: PMC8781152 DOI: 10.3390/ijms23020987] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2021] [Accepted: 01/11/2022] [Indexed: 02/04/2023] Open
Abstract
Peroxisomal fatty acid α-oxidation is an essential pathway for the degradation of β-carbon methylated fatty acids such as phytanic acid. One enzyme in this pathway is 2-hydroxyacyl CoA lyase (HACL1), which is responsible for the cleavage of 2-hydroxyphytanoyl-CoA into pristanal and formyl-CoA. Hacl1 deficient mice do not present with a severe phenotype, unlike mice deficient in other α-oxidation enzymes such as phytanoyl-CoA hydroxylase deficiency (Refsum disease) in which neuropathy and ataxia are present. Tissues from wild-type and Hacl1−/− mice fed a high phytol diet were obtained for proteomic and lipidomic analysis. There was no phenotype observed in these mice. Liver, brain, and kidney tissues underwent trypsin digestion for untargeted proteomic liquid chromatography-mass spectrometry analysis, while liver tissues also underwent fatty acid hydrolysis, extraction, and derivatisation for fatty acid gas chromatography-mass spectrometry analysis. The liver fatty acid profile demonstrated an accumulation of phytanic and 2-hydroxyphytanic acid in the Hacl1−/− liver and significant decrease in heptadecanoic acid. The liver proteome showed a significant decrease in the abundance of Hacl1 and a significant increase in the abundance of proteins involved in PPAR signalling, peroxisome proliferation, and omega oxidation, particularly Cyp4a10 and Cyp4a14. In addition, the pathway associated with arachidonic acid metabolism was affected; Cyp2c55 was upregulated and Cyp4f14 and Cyp2b9 were downregulated. The kidney proteome revealed fewer significantly upregulated peroxisomal proteins and the brain proteome was not significantly different in Hacl1−/− mice. This study demonstrates the powerful insight brought by proteomic and metabolomic profiling of Hacl1−/− mice in better understanding disease mechanism in fatty acid α-oxidation disorders.
Collapse
Affiliation(s)
- Youssef Khalil
- Genetics and Genomic Medicine, Great Ormond Street Institute of Child Health, University College London, London WC1N 1EH, UK; (Y.K.); (S.C.); (F.M.); (W.H.); (K.M.)
| | - Sara Carrino
- Genetics and Genomic Medicine, Great Ormond Street Institute of Child Health, University College London, London WC1N 1EH, UK; (Y.K.); (S.C.); (F.M.); (W.H.); (K.M.)
- Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, 40138 Bologna, Italy
| | - Fujun Lin
- Department of Renal Medicine, University College London, London NW3 2PF, UK; (F.L.); (A.F.); (D.P.G.)
- Department of Nephrology, Xin Hua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200082, China
| | - Anna Ferlin
- Department of Renal Medicine, University College London, London NW3 2PF, UK; (F.L.); (A.F.); (D.P.G.)
- Clinical Genetics and Genomics Laboratory, Royal Brompton Hospital, London SW3 6NP, UK
| | - Heena V. Lad
- MRC Harwell Institute, Harwell Campus, Oxfordshire OX11 0RD, UK; (H.V.L.); (S.F.); (N.R.); (G.B.); (D.C.); (C.A.); (A.R.H.); (A.B.); (T.N.); (P.P.)
| | - Francesca Mazzacuva
- Genetics and Genomic Medicine, Great Ormond Street Institute of Child Health, University College London, London WC1N 1EH, UK; (Y.K.); (S.C.); (F.M.); (W.H.); (K.M.)
- Department of Bioscience, University of East London, London E15 4LZ, UK
| | - Sara Falcone
- MRC Harwell Institute, Harwell Campus, Oxfordshire OX11 0RD, UK; (H.V.L.); (S.F.); (N.R.); (G.B.); (D.C.); (C.A.); (A.R.H.); (A.B.); (T.N.); (P.P.)
| | - Natalie Rivers
- MRC Harwell Institute, Harwell Campus, Oxfordshire OX11 0RD, UK; (H.V.L.); (S.F.); (N.R.); (G.B.); (D.C.); (C.A.); (A.R.H.); (A.B.); (T.N.); (P.P.)
| | - Gareth Banks
- MRC Harwell Institute, Harwell Campus, Oxfordshire OX11 0RD, UK; (H.V.L.); (S.F.); (N.R.); (G.B.); (D.C.); (C.A.); (A.R.H.); (A.B.); (T.N.); (P.P.)
| | - Danilo Concas
- MRC Harwell Institute, Harwell Campus, Oxfordshire OX11 0RD, UK; (H.V.L.); (S.F.); (N.R.); (G.B.); (D.C.); (C.A.); (A.R.H.); (A.B.); (T.N.); (P.P.)
| | - Carlos Aguilar
- MRC Harwell Institute, Harwell Campus, Oxfordshire OX11 0RD, UK; (H.V.L.); (S.F.); (N.R.); (G.B.); (D.C.); (C.A.); (A.R.H.); (A.B.); (T.N.); (P.P.)
| | - Andrew R. Haynes
- MRC Harwell Institute, Harwell Campus, Oxfordshire OX11 0RD, UK; (H.V.L.); (S.F.); (N.R.); (G.B.); (D.C.); (C.A.); (A.R.H.); (A.B.); (T.N.); (P.P.)
| | - Andy Blease
- MRC Harwell Institute, Harwell Campus, Oxfordshire OX11 0RD, UK; (H.V.L.); (S.F.); (N.R.); (G.B.); (D.C.); (C.A.); (A.R.H.); (A.B.); (T.N.); (P.P.)
| | - Thomas Nicol
- MRC Harwell Institute, Harwell Campus, Oxfordshire OX11 0RD, UK; (H.V.L.); (S.F.); (N.R.); (G.B.); (D.C.); (C.A.); (A.R.H.); (A.B.); (T.N.); (P.P.)
| | - Raya Al-Shawi
- Genetics Unit and Wolfson Drug Discovery Unit, Centre for Amyloidosis and Acute Phase Proteins, University College London, London NW3 2PF, UK;
| | - Wendy Heywood
- Genetics and Genomic Medicine, Great Ormond Street Institute of Child Health, University College London, London WC1N 1EH, UK; (Y.K.); (S.C.); (F.M.); (W.H.); (K.M.)
| | - Paul Potter
- MRC Harwell Institute, Harwell Campus, Oxfordshire OX11 0RD, UK; (H.V.L.); (S.F.); (N.R.); (G.B.); (D.C.); (C.A.); (A.R.H.); (A.B.); (T.N.); (P.P.)
| | - Kevin Mills
- Genetics and Genomic Medicine, Great Ormond Street Institute of Child Health, University College London, London WC1N 1EH, UK; (Y.K.); (S.C.); (F.M.); (W.H.); (K.M.)
| | - Daniel P. Gale
- Department of Renal Medicine, University College London, London NW3 2PF, UK; (F.L.); (A.F.); (D.P.G.)
| | - Peter T. Clayton
- Genetics and Genomic Medicine, Great Ormond Street Institute of Child Health, University College London, London WC1N 1EH, UK; (Y.K.); (S.C.); (F.M.); (W.H.); (K.M.)
- Correspondence:
| |
Collapse
|
5
|
Integrative analysis of proteomic and metabonomics data for identification of pathways related to Rhizoma Paridis-induced hepatotoxicity. Sci Rep 2020; 10:6540. [PMID: 32300172 PMCID: PMC7162872 DOI: 10.1038/s41598-020-63632-1] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2019] [Accepted: 04/03/2020] [Indexed: 12/21/2022] Open
Abstract
Clinical reports on hepatotoxicity that arise from Rhizoma Paridis have recently received widespread attention. Because the hepatotoxicity mechanism is little understood, this research strived to investigate the hepatotoxicity mechanism of Rhizoma Paridis extracts based on iTRAQ quantitative proteomics and metabonomics. The extraction solutions were administrated to rats for 7 days by gavage, and the hepatotoxicity was assessed through quantification of biochemical indexes and Oil red O staining. Additionally, the mechanism of hepatotoxicity was investigated by metabonomics based upon GC-MS and iTRAQ quantitative proteomics. The biochemical and histopathological analysis stood out that Rhizoma Paridis extract could induce liver injury, which was proved by the formation of fat droplets, the changes of mitochondrial structure, and biochemical parameters. The iTRAQ proteomics and metabonomics revealed that Rhizoma Paridis-induced hepatotoxicity was chiefly connected with the abnormal activity of mitochondrion function, which brought about oxidative stress injuries and inflammation, finally causing cell apoptosis. Collectively, we have provided previously uncharacterized hepatotoxic mechanism induced by Rhizoma Paridis and a reference to ensure its safe use in the future.
Collapse
|
6
|
Berendse K, Koot BGP, Klouwer FCC, Engelen M, Roels F, Lacle MM, Nikkels PGJ, Verheij J, Poll-The BT. Hepatic symptoms and histology in 13 patients with a Zellweger spectrum disorder. J Inherit Metab Dis 2019; 42:955-965. [PMID: 31150129 DOI: 10.1002/jimd.12132] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/30/2018] [Revised: 05/26/2019] [Accepted: 05/29/2019] [Indexed: 12/18/2022]
Abstract
Patients with a Zellweger spectrum disorder (ZSD) have a defect in the assembly or maintenance of peroxisomes, leading to a multisystem disease with variable outcome. Liver disease is an important feature in patients with severe and milder phenotypes and a frequent cause of death. However, the course and histology of liver disease in ZSD patients are ill-defined. We reviewed the hepatic symptoms and histological findings of 13 patients with a ZSD in which one or several liver biopsies have been performed (patient age 0.2-39 years). All patients had at least some histological liver abnormalities, ranging from minor fibrosis to cirrhosis. Five patients demonstrated significant disease progression with liver failure and early death. In others, liver-related symptoms were absent, although some still silently developed cirrhosis. Patients with peroxisomal mosaicism had a better prognosis. In addition, we show that patients are at risk to develop a hepatocellular carcinoma (HCC), as one patient developed a HCC at the age of 36 years and one patient a precancerous lesion at the age of 18 years. Thus, regular examination to detect fibrosis or cirrhosis should be included in the standard care of ZSD patients. In case of advanced fibrosis/cirrhosis expert consultation and HCC screening should be initiated. This study further delineates the spectrum and significance of liver involvement in ZSDs.
Collapse
Affiliation(s)
- Kevin Berendse
- Department of Paediatric Neurology, Emma Children's Hospital, Amsterdam University Medical Centre (Amsterdam UMC), University of Amsterdam, Amsterdam, The Netherlands
| | - Bart G P Koot
- Department of Paediatric Gastroenterology, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
| | - Femke C C Klouwer
- Department of Paediatric Neurology, Emma Children's Hospital, Amsterdam University Medical Centre (Amsterdam UMC), University of Amsterdam, Amsterdam, The Netherlands
| | - Marc Engelen
- Department of Paediatric Neurology, Emma Children's Hospital, Amsterdam University Medical Centre (Amsterdam UMC), University of Amsterdam, Amsterdam, The Netherlands
| | - Frank Roels
- Department of Human Anatomy and Embryology, Ghent University, Ghent, Belgium
| | - Miangela M Lacle
- Department of Pathology, University Medical Centre Utrecht, Utrecht, The Netherlands
| | - Peter G J Nikkels
- Department of Pathology, University Medical Centre Utrecht, Utrecht, The Netherlands
| | - Joanne Verheij
- Department of Pathology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
| | | |
Collapse
|
7
|
Phytol and its metabolites phytanic and pristanic acids for risk of cancer: current evidence and future directions. Eur J Cancer Prev 2019; 29:191-200. [PMID: 31436750 PMCID: PMC7012361 DOI: 10.1097/cej.0000000000000534] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
This review summarizes the current evidence on the potential role of phytol, a microbial metabolite of chlorophyl A, and its metabolites, phytanic and pristanic acids, in carcinogenesis. Primary food sources in Western diets are the nut skin for phytol and lipids in dairy, beef and fish for its metabolites. Phytol and its metabolites gained interest as dietary compounds for cancer prevention because, as natural ligands of peroxisome proliferator-activated receptor-α and -γ and retinoid X receptor, phytol and its metabolites have provided some evidence in cell culture studies and limited evidence in animal models of anti-carcinogenic, anti-inflammatory and anti-metabolic-syndrome properties at physiological concentrations. However, there may be a narrow range of efficacy, because phytol and its metabolites at supra-physiological concentrations can cause in vitro cytotoxicity in non-cancer cells and can cause morbidity and mortality in animal models. In human studies, evidence for a role of phytol and its metabolites in cancer prevention is currently limited and inconclusive. In short, phytol and its metabolites are potential dietary compounds for cancer prevention, assuming the challenges in preventing cytotoxicity in non-cancer cells and animal models and understanding phytol metabolism can be mitigated.
Collapse
|
8
|
Roca-Saavedra P, Mariño-Lorenzo P, Miranda J, Porto-Arias J, Lamas A, Vazquez B, Franco C, Cepeda A. Phytanic acid consumption and human health, risks, benefits and future trends: A review. Food Chem 2017; 221:237-247. [DOI: 10.1016/j.foodchem.2016.10.074] [Citation(s) in RCA: 30] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2016] [Revised: 09/29/2016] [Accepted: 10/18/2016] [Indexed: 12/18/2022]
|
9
|
Jenkins BJ, Seyssel K, Chiu S, Pan PH, Lin SY, Stanley E, Ament Z, West JA, Summerhill K, Griffin JL, Vetter W, Autio KJ, Hiltunen K, Hazebrouck S, Stepankova R, Chen CJ, Alligier M, Laville M, Moore M, Kraft G, Cherrington A, King S, Krauss RM, de Schryver E, Van Veldhoven PP, Ronis M, Koulman A. Odd Chain Fatty Acids; New Insights of the Relationship Between the Gut Microbiota, Dietary Intake, Biosynthesis and Glucose Intolerance. Sci Rep 2017; 7:44845. [PMID: 28332596 PMCID: PMC5362956 DOI: 10.1038/srep44845] [Citation(s) in RCA: 82] [Impact Index Per Article: 11.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2016] [Accepted: 02/14/2017] [Indexed: 02/03/2023] Open
Abstract
Recent findings have shown an inverse association between circulating C15:0/C17:0 fatty acids with disease risk, therefore, their origin needs to be determined to understanding their role in these pathologies. Through combinations of both animal and human intervention studies, we comprehensively investigated all possible contributions of these fatty acids from the gut-microbiota, the diet, and novel endogenous biosynthesis. Investigations included an intestinal germ-free study and a C15:0/C17:0 diet dose response study. Endogenous production was assessed through: a stearic acid infusion, phytol supplementation, and a Hacl1−/− mouse model. Two human dietary intervention studies were used to translate the results. Finally, a study comparing baseline C15:0/C17:0 with the prognosis of glucose intolerance. We found that circulating C15:0/C17:0 levels were not influenced by the gut-microbiota. The dose response study showed C15:0 had a linear response, however C17:0 was not directly correlated. The phytol supplementation only decreased C17:0. Stearic acid infusion only increased C17:0. Hacl1−/− only decreased C17:0. The glucose intolerance study showed only C17:0 correlated with prognosis. To summarise, circulating C15:0 and C17:0 are independently derived; C15:0 correlates directly with dietary intake, while C17:0 is substantially biosynthesized, therefore, they are not homologous in the aetiology of metabolic disease. Our findings emphasize the importance of the biosynthesis of C17:0 and recognizing its link with metabolic disease.
Collapse
Affiliation(s)
- Benjamin J Jenkins
- Medical Research Council Human Nutrition Research, Elsie Widdowson Laboratory, Fulbourn Road, Cambridge, CB1 9NL. Affiliated with the University of Cambridge, United Kingdom
| | - Kevin Seyssel
- Lyon University, INSERM U1060, CarMeN Laboratory and CENS, Claude Bernard University, CRNH Rhône-Alpes, Centre Hospitalier Lyon-Sud, 69310, Pierre-Bénite, France
| | - Sally Chiu
- Children's Hospital Oakland Research Institute, 5700 Martin Luther King Jr. Way, Oakland, CA 94609, United States of America
| | - Pin-Ho Pan
- Department of Pediatrics, Tungs' Taichung MetroHarbor Hospital, Taichung 435, Taiwan
| | - Shih-Yi Lin
- Division of Endocrinology and Metabolism/Center for Geriatrics and Gerontology, Taichung Veterans General Hospital, No. 1650, Sec. 4, Taiwan Boulevard, Taichung 407, Taiwan
| | - Elizabeth Stanley
- Medical Research Council Human Nutrition Research, Elsie Widdowson Laboratory, Fulbourn Road, Cambridge, CB1 9NL. Affiliated with the University of Cambridge, United Kingdom
| | - Zsuzsanna Ament
- Medical Research Council Human Nutrition Research, Elsie Widdowson Laboratory, Fulbourn Road, Cambridge, CB1 9NL. Affiliated with the University of Cambridge, United Kingdom
| | - James A West
- Medical Research Council Human Nutrition Research, Elsie Widdowson Laboratory, Fulbourn Road, Cambridge, CB1 9NL. Affiliated with the University of Cambridge, United Kingdom
| | - Keith Summerhill
- Medical Research Council Human Nutrition Research, Elsie Widdowson Laboratory, Fulbourn Road, Cambridge, CB1 9NL. Affiliated with the University of Cambridge, United Kingdom
| | - Julian L Griffin
- Medical Research Council Human Nutrition Research, Elsie Widdowson Laboratory, Fulbourn Road, Cambridge, CB1 9NL. Affiliated with the University of Cambridge, United Kingdom
| | - Walter Vetter
- University of Hohenheim, Institute of Food Chemistry, Garbenstrasse 28, D-70599 Stuttgart, Germany
| | - Kaija J Autio
- Faculty of Biochemistry and Molecular Medicine, Biocenter Oulu, University of Oulu, P.O. Box 5400, FI-90014, Finland
| | - Kalervo Hiltunen
- Faculty of Biochemistry and Molecular Medicine, Biocenter Oulu, University of Oulu, P.O. Box 5400, FI-90014, Finland
| | - Stéphane Hazebrouck
- UMR CEA-INRA Service de Pharmacologie et d'Immunoanalyse, Laboratoire d'Immuno-Allergie Alimentaire, Université Paris-Saclay, F-91991 Gif-sur-Yvette, France
| | - Renata Stepankova
- Laboratory of Gnotobiology, Institute of Microbiology, Czech Academy of Science, Novy Hradek, 549 22, Prague, Czech Republic
| | - Chun-Jung Chen
- Department of Medical Research, Taichung Veterans General Hospital, No. 1650, Sec.4, Taiwan Boulevard, Taichung 407, Taiwan
| | - Maud Alligier
- Lyon University, INSERM U1060, CarMeN Laboratory and CENS, Claude Bernard University, CRNH Rhône-Alpes, Centre Hospitalier Lyon-Sud, 69310, Pierre-Bénite, France
| | - Martine Laville
- Lyon University, INSERM U1060, CarMeN Laboratory and CENS, Claude Bernard University, CRNH Rhône-Alpes, Centre Hospitalier Lyon-Sud, 69310, Pierre-Bénite, France
| | - Mary Moore
- 702 Light Hall, Dept. of Molecular Physiology &Biophysics, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-0615, United States of America
| | - Guillaume Kraft
- 702 Light Hall, Dept. of Molecular Physiology &Biophysics, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-0615, United States of America
| | - Alan Cherrington
- 702 Light Hall, Dept. of Molecular Physiology &Biophysics, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-0615, United States of America
| | - Sarah King
- Children's Hospital Oakland Research Institute, 5700 Martin Luther King Jr. Way, Oakland, CA 94609, United States of America
| | - Ronald M Krauss
- Children's Hospital Oakland Research Institute, 5700 Martin Luther King Jr. Way, Oakland, CA 94609, United States of America
| | - Evelyn de Schryver
- Laboratory of Lipid Biochemistry and Protein Interactions (LIPIT), Campus Gasthuisberg - KU Leuven, Herestraat Box 601, B-3000 Leuven, Belgium
| | - Paul P Van Veldhoven
- Laboratory of Lipid Biochemistry and Protein Interactions (LIPIT), Campus Gasthuisberg - KU Leuven, Herestraat Box 601, B-3000 Leuven, Belgium
| | - Martin Ronis
- College of Medicine, Department of Pharmacology &Experimental Therapeutics, Louisiana State University Health Sciences Centre 1901 Perdido Str., New Orleans, United States of America
| | - Albert Koulman
- Medical Research Council Human Nutrition Research, Elsie Widdowson Laboratory, Fulbourn Road, Cambridge, CB1 9NL. Affiliated with the University of Cambridge, United Kingdom.,NIHR BRC Core Metabolomics and Lipidomics Laboratory, Level 4, Laboratory Block, Cambridge University Hospitals, University of Cambridge, Cambridge, UK
| |
Collapse
|
10
|
Tafferner N, Barthelmes J, Eberle M, Ulshöfer T, Henke M, deBruin N, Mayer CA, Foerch C, Geisslinger G, Parnham MJ, Schiffmann S. Alpha-methylacyl-CoA racemase deletion has mutually counteracting effects on T-cell responses, associated with unchanged course of EAE. Eur J Immunol 2016; 46:570-81. [DOI: 10.1002/eji.201545782] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2015] [Revised: 11/05/2015] [Accepted: 12/02/2015] [Indexed: 12/13/2022]
Affiliation(s)
- Nadja Tafferner
- Fraunhofer Institute for Molecular Biology and Applied Ecology IME; Project Group Translational Medicine and Pharmacology (TMP); Frankfurt am Main Germany
| | - Julia Barthelmes
- Pharmazentrum Frankfurt/ZAFES; Institute of Clinical Pharmacology; Goethe-University Hospital Frankfurt; Frankfurt/Main Germany
| | - Max Eberle
- Pharmazentrum Frankfurt/ZAFES; Institute of Clinical Pharmacology; Goethe-University Hospital Frankfurt; Frankfurt/Main Germany
| | - Thomas Ulshöfer
- Fraunhofer Institute for Molecular Biology and Applied Ecology IME; Project Group Translational Medicine and Pharmacology (TMP); Frankfurt am Main Germany
| | - Marina Henke
- Fraunhofer Institute for Molecular Biology and Applied Ecology IME; Project Group Translational Medicine and Pharmacology (TMP); Frankfurt am Main Germany
| | - Natasja deBruin
- Fraunhofer Institute for Molecular Biology and Applied Ecology IME; Project Group Translational Medicine and Pharmacology (TMP); Frankfurt am Main Germany
| | - Christoph A. Mayer
- Department of Neurology; Goethe-University Frankfurt; Frankfurt/Main Germany
| | - Christian Foerch
- Department of Neurology; Goethe-University Frankfurt; Frankfurt/Main Germany
| | - Gerd Geisslinger
- Pharmazentrum Frankfurt/ZAFES; Institute of Clinical Pharmacology; Goethe-University Hospital Frankfurt; Frankfurt/Main Germany
| | - Michael J. Parnham
- Fraunhofer Institute for Molecular Biology and Applied Ecology IME; Project Group Translational Medicine and Pharmacology (TMP); Frankfurt am Main Germany
| | - Susanne Schiffmann
- Pharmazentrum Frankfurt/ZAFES; Institute of Clinical Pharmacology; Goethe-University Hospital Frankfurt; Frankfurt/Main Germany
| |
Collapse
|
11
|
Berger J, Dorninger F, Forss-Petter S, Kunze M. Peroxisomes in brain development and function. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH 2015; 1863:934-55. [PMID: 26686055 PMCID: PMC4880039 DOI: 10.1016/j.bbamcr.2015.12.005] [Citation(s) in RCA: 120] [Impact Index Per Article: 13.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/15/2015] [Revised: 12/04/2015] [Accepted: 12/09/2015] [Indexed: 12/26/2022]
Abstract
Peroxisomes contain numerous enzymatic activities that are important for mammalian physiology. Patients lacking either all peroxisomal functions or a single enzyme or transporter function typically develop severe neurological deficits, which originate from aberrant development of the brain, demyelination and loss of axonal integrity, neuroinflammation or other neurodegenerative processes. Whilst correlating peroxisomal properties with a compilation of pathologies observed in human patients and mouse models lacking all or individual peroxisomal functions, we discuss the importance of peroxisomal metabolites and tissue- and cell type-specific contributions to the observed brain pathologies. This enables us to deconstruct the local and systemic contribution of individual metabolic pathways to specific brain functions. We also review the recently discovered variability of pathological symptoms in cases with unexpectedly mild presentation of peroxisome biogenesis disorders. Finally, we explore the emerging evidence linking peroxisomes to more common neurological disorders such as Alzheimer’s disease, autism and amyotrophic lateral sclerosis. This article is part of a Special Issue entitled: Peroxisomes edited by Ralf Erdmann.
Collapse
Affiliation(s)
- Johannes Berger
- Department of Pathobiology of the Nervous System, Center for Brain Research, Medical University of Vienna, Spitalgasse 4, 1090 Vienna, Austria.
| | - Fabian Dorninger
- Department of Pathobiology of the Nervous System, Center for Brain Research, Medical University of Vienna, Spitalgasse 4, 1090 Vienna, Austria.
| | - Sonja Forss-Petter
- Department of Pathobiology of the Nervous System, Center for Brain Research, Medical University of Vienna, Spitalgasse 4, 1090 Vienna, Austria.
| | - Markus Kunze
- Department of Pathobiology of the Nervous System, Center for Brain Research, Medical University of Vienna, Spitalgasse 4, 1090 Vienna, Austria.
| |
Collapse
|